Cargando…
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
BACKGROUND. This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as...
Autores principales: | Moriwaki, Toshikazu, Fukuoka, Shota, Taniguchi, Hiroya, Takashima, Atsuo, Kumekawa, Yusuke, Kajiwara, Takeshi, Yamazaki, Kentaro, Esaki, Taito, Makiyama, Chinatsu, Denda, Tadamichi, Satake, Hironaga, Suto, Takeshi, Sugimoto, Naotoshi, Enomoto, Masanobu, Ishikawa, Toshiaki, Kashiwada, Tomomi, Sugiyama, Masahiko, Komatsu, Yoshito, Okuyama, Hiroyuki, Baba, Eishi, Sakai, Daisuke, Watanabe, Tomoki, Tamura, Takao, Yamashita, Kimihiro, Gosho, Masahiko, Shimada, Yasuhiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759812/ https://www.ncbi.nlm.nih.gov/pubmed/28894015 http://dx.doi.org/10.1634/theoncologist.2017-0275 |
Ejemplares similares
-
Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
por: Chida, Keigo, et al.
Publicado: (2021) -
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study
por: Shiroyama, Mamiko, et al.
Publicado: (2023) -
Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
por: Nakajima, Hiromichi, et al.
Publicado: (2021) -
Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan
por: Ogata, Misato, et al.
Publicado: (2020) -
Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021)